2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival time
2019
A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
Klimov S, Miligy I, Gertych A, Jiang Y, Toss M, Rida P, Ellis I, Green A, Krishnamurti U, Rakha E, Aneja R. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research 2019, 21: 83. PMID: 31358020, PMCID: PMC6664779, DOI: 10.1186/s13058-019-1165-5.Peer-Reviewed Original ResearchConceptsDCIS patientsRecurrence riskDuctal carcinomaScreen-detected breast cancerLong-term outcome dataBreast-conserving surgeryUnmet clinical needNottingham University HospitalsPositive predictive valueAdjuvant radiationIpsilateral recurrenceAdditional therapyMethodsThe cohortHazard ratioLocal recurrenceClinicopathological markersClinicopathological variablesPrimary tumorUniversity HospitalLymphocyte regionBreast cancerOutcome dataBenign ductsPredictive valuePatients